HCV根除对晚期纤维化或肝硬化HIV患者与MASLD相关的脂质谱的长期影响

IF 4 3区医学 Q1 INFECTIOUS DISEASES

Journal of Infection and Public Health Pub Date : 2025-09-27 DOI:10.1016/j.jiph.2025.102981

Ana Virseda-Berdices , Belen Requena , Juan Berenguer , Juan Gónzalez-García , Carolina Gonzalez-Riano , Cristina Díez , Victor Hontañón , Paula Muñoz-García , Amanda Fernández-Rodríguez , Coral Barbas , Salvador Resino , Rubén Martín-Escolano , María Ángeles Jiménez-Sousa , the Marathon Study Group

{"title":"HCV根除对晚期纤维化或肝硬化HIV患者与MASLD相关的脂质谱的长期影响","authors":"Ana Virseda-Berdices , Belen Requena , Juan Berenguer , Juan Gónzalez-García , Carolina Gonzalez-Riano , Cristina Díez , Victor Hontañón , Paula Muñoz-García , Amanda Fernández-Rodríguez , Coral Barbas , Salvador Resino , Rubén Martín-Escolano , María Ángeles Jiménez-Sousa , the Marathon Study Group","doi":"10.1016/j.jiph.2025.102981","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Despite successful hepatitis C virus (HCV) clearance, some individuals continue to experience liver disease progression. Metabolic dysfunction-associated steatotic liver disease (MASLD) may play a key role in this ongoing progression. This study aims to characterize the lipidomic profiles associated with MASLD in individuals coinfected with human immunodeficiency virus (HIV) and HCV with advanced fibrosis or cirrhosis after sustained virologic response (SVR).</div></div><div><h3>Methods</h3><div>We conducted cross-sectional studies in fifty-two HIV/HCV-coinfected individuals. Untargeted lipidomics was performed on plasma samples collected at 1 year and 6 years post-SVR using liquid chromatography-mass spectrometry. The primary outcome was MASLD. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA) and generalized linear models (GLM), with corrections for multiple comparisons.</div></div><div><h3>Results</h3><div>The prevalence of MASLD was 28.9 % one year after SVR, increasing to 44.8 % six years after SVR. OPLS-DA models identified 225 lipids at 1 year and 167 at 6 years, with a VIP score ≥ 1, distinguishing individuals based on MASLD status. Adjusted GLMs confirmed significant associations between MASLD and 116 lipids at 1 year and 49 at 6 years. At 1 year, most significant lipids were glycerophospholipids (GP), with increased phosphatidylcholines (PC) and phosphatidylethanolamines (PE), and decreased lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE). By 6 years, LPC was the most abundant differential lipid, while triglycerides increased significantly.</div></div><div><h3>Conclusions</h3><div>MASLD was common during follow-up, with changes in lipidomic profiles over time suggesting ongoing metabolic disturbances that may contribute to liver disease progression despite SVR. These findings highlight the need for long-term metabolic and liver health monitoring after HCV eradication in these individuals.</div></div>","PeriodicalId":16087,"journal":{"name":"Journal of Infection and Public Health","volume":"18 12","pages":"Article 102981"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis\",\"authors\":\"Ana Virseda-Berdices , Belen Requena , Juan Berenguer , Juan Gónzalez-García , Carolina Gonzalez-Riano , Cristina Díez , Victor Hontañón , Paula Muñoz-García , Amanda Fernández-Rodríguez , Coral Barbas , Salvador Resino , Rubén Martín-Escolano , María Ángeles Jiménez-Sousa , the Marathon Study Group\",\"doi\":\"10.1016/j.jiph.2025.102981\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Despite successful hepatitis C virus (HCV) clearance, some individuals continue to experience liver disease progression. Metabolic dysfunction-associated steatotic liver disease (MASLD) may play a key role in this ongoing progression. This study aims to characterize the lipidomic profiles associated with MASLD in individuals coinfected with human immunodeficiency virus (HIV) and HCV with advanced fibrosis or cirrhosis after sustained virologic response (SVR).</div></div><div><h3>Methods</h3><div>We conducted cross-sectional studies in fifty-two HIV/HCV-coinfected individuals. Untargeted lipidomics was performed on plasma samples collected at 1 year and 6 years post-SVR using liquid chromatography-mass spectrometry. The primary outcome was MASLD. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA) and generalized linear models (GLM), with corrections for multiple comparisons.</div></div><div><h3>Results</h3><div>The prevalence of MASLD was 28.9 % one year after SVR, increasing to 44.8 % six years after SVR. OPLS-DA models identified 225 lipids at 1 year and 167 at 6 years, with a VIP score ≥ 1, distinguishing individuals based on MASLD status. Adjusted GLMs confirmed significant associations between MASLD and 116 lipids at 1 year and 49 at 6 years. At 1 year, most significant lipids were glycerophospholipids (GP), with increased phosphatidylcholines (PC) and phosphatidylethanolamines (PE), and decreased lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE). By 6 years, LPC was the most abundant differential lipid, while triglycerides increased significantly.</div></div><div><h3>Conclusions</h3><div>MASLD was common during follow-up, with changes in lipidomic profiles over time suggesting ongoing metabolic disturbances that may contribute to liver disease progression despite SVR. These findings highlight the need for long-term metabolic and liver health monitoring after HCV eradication in these individuals.</div></div>\",\"PeriodicalId\":16087,\"journal\":{\"name\":\"Journal of Infection and Public Health\",\"volume\":\"18 12\",\"pages\":\"Article 102981\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infection and Public Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1876034125003302\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Public Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876034125003302","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

背景：尽管成功清除了丙型肝炎病毒（HCV），但一些个体继续经历肝脏疾病的进展。代谢功能障碍相关的脂肪变性肝病（MASLD）可能在这一持续进展中起关键作用。本研究旨在描述持续病毒学应答（SVR）后伴有晚期纤维化或肝硬化的人类免疫缺陷病毒（HIV）和HCV合并感染个体与MASLD相关的脂质组学特征。方法：我们对52例HIV/ hcv合并感染者进行了横断面研究。使用液相色谱-质谱法对svr后1年和6年收集的血浆样本进行非靶向脂质组学。主要结局是MASLD。统计分析包括正交偏最小二乘判别分析（OPLS-DA）和广义线性模型（GLM），并对多重比较进行校正。结果：SVR后1年MASLD患病率为28.9 %，SVR后6年患病率为44.8 %。OPLS-DA模型在1年时鉴定出225种脂质，在6年时鉴定出167种脂质，VIP评分≥ 1，根据MASLD状态区分个体。调整后的GLMs证实MASLD与1年时116种血脂和6年时49种血脂之间存在显著关联。1年时，最显著的脂质是甘油磷脂（GP），磷脂酰胆碱（PC）和磷脂酰乙醇胺（PE）增加，溶血磷脂酰胆碱（LPC）和溶血磷脂酰乙醇胺（LPE）减少。到6岁时，LPC是最丰富的差异脂质，甘油三酯显著增加。结论：在随访期间，MASLD很常见，随着时间的推移，脂质组学特征的变化表明，尽管SVR存在，但持续的代谢紊乱可能导致肝病进展。这些发现强调了这些个体在根除HCV后需要进行长期代谢和肝脏健康监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Long-term effects of HCV eradication on lipid profiles associated with MASLD among people with HIV with advanced fibrosis or cirrhosis

Background

Despite successful hepatitis C virus (HCV) clearance, some individuals continue to experience liver disease progression. Metabolic dysfunction-associated steatotic liver disease (MASLD) may play a key role in this ongoing progression. This study aims to characterize the lipidomic profiles associated with MASLD in individuals coinfected with human immunodeficiency virus (HIV) and HCV with advanced fibrosis or cirrhosis after sustained virologic response (SVR).

Methods

We conducted cross-sectional studies in fifty-two HIV/HCV-coinfected individuals. Untargeted lipidomics was performed on plasma samples collected at 1 year and 6 years post-SVR using liquid chromatography-mass spectrometry. The primary outcome was MASLD. Statistical analyses included orthogonal partial least squares discriminant analysis (OPLS-DA) and generalized linear models (GLM), with corrections for multiple comparisons.

Results

The prevalence of MASLD was 28.9 % one year after SVR, increasing to 44.8 % six years after SVR. OPLS-DA models identified 225 lipids at 1 year and 167 at 6 years, with a VIP score ≥ 1, distinguishing individuals based on MASLD status. Adjusted GLMs confirmed significant associations between MASLD and 116 lipids at 1 year and 49 at 6 years. At 1 year, most significant lipids were glycerophospholipids (GP), with increased phosphatidylcholines (PC) and phosphatidylethanolamines (PE), and decreased lysophosphatidylcholines (LPC) and lysophosphatidylethanolamines (LPE). By 6 years, LPC was the most abundant differential lipid, while triglycerides increased significantly.

Conclusions

MASLD was common during follow-up, with changes in lipidomic profiles over time suggesting ongoing metabolic disturbances that may contribute to liver disease progression despite SVR. These findings highlight the need for long-term metabolic and liver health monitoring after HCV eradication in these individuals.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Infection and Public Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -INFECTIOUS DISEASES

CiteScore

13.10

自引率

1.50%

发文量

203

审稿时长

96 days

期刊介绍： The Journal of Infection and Public Health, first official journal of the Saudi Arabian Ministry of National Guard Health Affairs, King Saud Bin Abdulaziz University for Health Sciences and the Saudi Association for Public Health, aims to be the foremost scientific, peer-reviewed journal encompassing infection prevention and control, microbiology, infectious diseases, public health and the application of healthcare epidemiology to the evaluation of health outcomes. The point of view of the journal is that infection and public health are closely intertwined and that advances in one area will have positive consequences on the other. The journal will be useful to all health professionals who are partners in the management of patients with communicable diseases, keeping them up to date. The journal is proud to have an international and diverse editorial board that will assist and facilitate the publication of articles that reflect a global view on infection control and public health, as well as emphasizing our focus on supporting the needs of public health practitioners. It is our aim to improve healthcare by reducing risk of infection and related adverse outcomes by critical review, selection, and dissemination of new and relevant information in the field of infection control, public health and infectious diseases in all healthcare settings and the community.